Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia

Sorigué, Marc; Magnano, Laura; Miljković, Miloš D.; Nieto‐Moragas, Javier; Santos‐Gomez, Mireia; Villamor, Neus; Juncà, Jordi; Morales‐Indiano, Cristian

doi:10.1002/cyto.b.21849

Cited by 14 publications

(14 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another recent study, Sorigue et al conducted a systematic review of the use of CD200 in the differential diagnosis of CLPDs (71). They evaluated the positive predictive value of CD200 on the prevalence of the disorders evaluated for the differential diagnosis.…”

Section: Relevance Of Cd200 In Diagnosis Of Chronic Lymphoproliferatimentioning

confidence: 99%

CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance

D’Arena¹,

Feo

Pietrantuono

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

CD200, a transmembrane type Ia glycoprotein belonging to the immunoglobulin protein superfamily, is broadly expressed on a wide variety of cell types, such as B lymphocytes, a subset of T lymphocytes, dendritic cells, endothelial and neuronal cells. It delivers immunosuppressive signals through its receptor CD200R, which is expressed on monocytes/myeloid cells and T lymphocytes. Moreover, interaction of CD200 with CD200R has also been reported to play a role in the regulation of tumor immunity. Overexpression of CD200 has been reported in chronic lymphocytic leukemia (CLL) and hairy cell leukemia but not in mantle cell lymphoma, thus helping to better discriminate between these different B cell malignancies with different prognosis. In this review, we focus on the role of CD200 expression in the differential diagnosis of mature B-cell neoplasms and on the prognostic significance of CD200 expression in CLL, where conflicting results have been published so far. Of interest, increasing evidences indicate that anti-CD200 treatment might be therapeutically beneficial for treating CD200-expressing malignancies, such as CLL.

show abstract

Section: Relevance Of Cd200 In Diagnosis Of Chronic Lymphoproliferatimentioning

confidence: 99%

CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance

D’Arena¹,

Feo

Pietrantuono

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…CD200 transmits inhibitory signals, resulting in the suppression of T-cellmediated immune activation. CD200 and its ligand CD200R play important roles in the regulation of antitumor activity [27][28][29][30]. Recent reports have proven that CD200 immunophenotyping is useful in the differential diagnosis of B-cell neoplasms.…”

Section: Cd200 Positivity In Indolent MCLmentioning

confidence: 99%

“…In earlier studies, CD200 was proven to be a useful marker for distinguishing CLL from MCL via flow cytometry [27]. However, several recent studies have demonstrated that the IgH-cyclin D1 rearrangement is necessary for the differential diagnosis between MCL and CLL/SLL [30,33]. CD200 is also a reliable auxiliary marker for classic prognostic factors [29].…”

Section: Cd200 Positivity In Indolent MCLmentioning

confidence: 99%

Progress in molecular feature of smoldering mantle cell lymphoma

Jiang

Desai

2021

Exp Hematol Oncol

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) is considered one of the most aggressive lymphoid tumors. However, it sometimes displays indolent behavior in patients and might not necessitate treatment at diagnosis; this has been described as “smoldering MCL” (SMCL). There are significant differences in the diagnosis, prognosis, molecular mechanisms and treatments of indolent MCL and classical MCL. In this review, we discuss the progress in understanding the molecular mechanism of indolent MCL to provide insights into the genomic nature of this entity. Reported findings of molecular features of indolent MCL include a low Ki-67 index, CD200 positivity, a low frequency of mutations in TP53, a lack of SOX11, normal arrangement and expression of MYC, IGHV mutations, differences from classical MCL by L-MCL16 assays and MCL35 assays, an unmutated P16 status, few defects in ATM, no NOTCH1/2 mutation, Amp 11q gene mutation, no chr9 deletion, microRNA upregulation/downregulation, and low expression of several genes that have been valued in recent years (SPEN, SMARCA4, RANBP2, KMT2C, NSD2, CARD11, FBXW7, BIRC3, KMT2D, CELSR3, TRAF2, MAP3K14, HNRNPH1, Del 9p and/or Del 9q, SP140 and PCDH10). Based on the above molecular characteristics, we may distinguish indolent MCL from classical MCL. If so, indolent MCL will not be overtreated, whereas the treatment of classical MCL will not be delayed.

show abstract

“…Immunophenotyping of certain diseases with special markers, provides information on positive predictive value, such as CD200 for diagnosis of Chronic Lymphocytic Leukemia (CLL). It is specific except nodal MCL -Mantle Cell Lymphoma (37). PPV can be very useful when a combination of monoclonal antibody percentage positivity, fluorescence density, and percentage of cells in a cell population is used.…”

Section: Positive Predictive Valuementioning

confidence: 99%

Flow Cytometric Analyses of Lymphocyte Markers in Immune Oncology: A Comprehensive Guidance for Validation Practice According to Laws and Standards

et al. 2020

View full text Add to dashboard Cite

Many anticancer therapies such as antibody-based therapies, cellular therapeutics (e.g., genetically modified cells, regulators of cytokine signaling, and signal transduction), and other biologically tailored interventions strongly influence the immune system and require tools for research, diagnosis, and monitoring. In flow cytometry, in vitro diagnostic (IVD) test kits that have been compiled and validated by the manufacturer are not available for all requirements. Laboratories are therefore usually dependent on modifying commercially available assays or, most often, developing them to meet clinical needs. However, both variants must then undergo full validation to fulfill the IVD regulatory requirements. Flow cytometric immunophenotyping is a multiparametric analysis of parameters, some of which have to be repeatedly adjusted; that must be considered when developing specific antibody panels. Careful adjustments of general rules are required to meet legal and regulatory requirements in the analysis of these assays. Here, we describe the relevant regulatory framework for flow cytometry-based assays and describe methods for the introduction of new antibody combinations into routine work including development of performance specifications, validation, and statistical methodology for design and analysis of the experiments. The aim is to increase reliability, efficiency, and auditability after the introduction of in-house-developed flow cytometry assays.

show abstract

Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia

Cited by 14 publications

References 42 publications

CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance

CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance

Progress in molecular feature of smoldering mantle cell lymphoma

Flow Cytometric Analyses of Lymphocyte Markers in Immune Oncology: A Comprehensive Guidance for Validation Practice According to Laws and Standards

Contact Info

Product

Resources

About